Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the a...

Podrobná bibliografie
Hlavní autoři:	Mease, P, Kavanaugh, A, Coates, L, McInnes, I, Hojnik, M, Zhang, Y, Anderson, J, Dorr, A, Gladman, D
Médium:	Journal article
Jazyk:	English
Vydáno:	BMJ Publishing Group 2017

Podobné jednotky

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
Autor: Coates, L, a další
Vydáno: (2019)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
Autor: Kavanaugh, A, a další
Vydáno: (2024)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
Autor: Gladman, DD, a další
Vydáno: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
Autor: Mease, PJ, a další
Vydáno: (2020)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
Autor: Choy, E, a další
Vydáno: (2007)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
Autor: Coates, LC, a další
Vydáno: (2021)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
Autor: Kavanaugh, A, a další
Vydáno: (2005)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Autor: Coates, LC, a další
Vydáno: (2024)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
Autor: Landewé, R, a další
Vydáno: (2019)

Psoriatic arthritis
Autor: FitzGerald, O, a další
Vydáno: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Autor: Ogdie, A, a další
Vydáno: (2023)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
Autor: Désirée van der Heijde, a další
Vydáno: (2020-02-01)

Classification and outcome measures for psoriatic arthritis
Autor: Leung, Y, a další
Vydáno: (2018)

Measuring outcomes in psoriatic arthritis
Autor: Ogdie, A, a další
Vydáno: (2020)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Autor: Laura C. Coates, a další
Vydáno: (2024-02-01)

Considerations for the definition of remission criteria in psoriatic arthritis
Autor: Mease, P, a další
Vydáno: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
Autor: Orbai, A-M, a další
Vydáno: (2019)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
Autor: Alexis Ogdie, a další
Vydáno: (2023-05-01)

Assessing disease activity in psoriatic arthritis: a literature review
Autor: Tucker, L, a další
Vydáno: (2018)

Classification and Outcome Measures for Psoriatic Arthritis
Autor: Ying Ying Leung, a další
Vydáno: (2018-09-01)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
Autor: Soriano, ER, a další
Vydáno: (2023)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
Autor: Coates, L, a další
Vydáno: (2017)

Residual inflammation in psoriatic arthritis patients in stable minimal disease activity
Autor: Pierluigi Macchioni, a další
Vydáno: (2022-12-01)

Methotrexate in psoriasis and psoriatic arthritis
Autor: Coates, L, a další
Vydáno: (2020)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Autor: Helliwell, PS, a další
Vydáno: (2022)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
Autor: Ye, W, a další
Vydáno: (2018)

Sustained very low disease activity and remission in psoriatic arthritis patients
Autor: Lubrano, E, a další
Vydáno: (2019)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
Autor: Yazji, SM, a další
Vydáno: (2025)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
Autor: Strand, V, a další
Vydáno: (2022)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Autor: Ennio Lubrano, a další
Vydáno: (2019-08-01)

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
Autor: Silvia Scriffignano, a další
Vydáno: (2023-09-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
Autor: Coates, L, a další
Vydáno: (2021)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
Autor: Coates, L, a další
Vydáno: (2018)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
Autor: Mease, PJ, a další
Vydáno: (2019)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Autor: Atul Deodhar, a další
Vydáno: (2022-07-01)

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
Autor: Coates, L, a další
Vydáno: (2018)

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study
Autor: Rubén Queiro, a další
Vydáno: (2017-03-01)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
Autor: D.D. Gladman
Vydáno: (2011-09-01)

Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis
Autor: Alexander Egeberg, a další
Vydáno: (2018-03-01)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
Autor: Laura C. Coates, a další
Vydáno: (2018-08-01)